Hunting Cloud Network recently learned that Katy Medical, a biotechnology company specializing in tumor infiltrating lymphocyte therapy (TIL), announced the completion of a billion-dollar Pre-B round of financing, which was led by Fengyun Capital.
It is understood that this round of financing will be used to support Carty Medical's "Super TIL" cell therapy products to complete the IND declaration.
Previously, Katie Medical received A+ round investment from investment institutions such as Jianxin Medical Growth Fund.
Immunotherapy has become the general trend of tumor treatment. Although CAR-T therapy shines brilliantly in the field of hematological tumors, it is often ineffective for solid tumors that account for more than 90% of tumor patients, which is mainly due to the heterogeneity and microenvironment characteristics of solid tumors.
The treatment of tumor infiltrating lymphocytes (TIL) is the best solution to the problem of tumor heterogeneity, and it is considered as a new hope to overcome solid tumors. TIL therapy of Iovance Company in the United States was recognized as a breakthrough therapy by FDA in the United States, which means that TIL is expected to become a new generation of cell therapy drugs after CAR-T.
However, the current TIL therapy still faces many problems, such as tumor microenvironment, cell expansion process, preparation cycle and cost, etc. TIL therapy still has its natural limitations-it must rely on surgical tissues to obtain cell materials, which is often difficult for most advanced patients.
Tianyancha APP information shows that Beijing Kati Medical Technology Co., Ltd. was established in June 2065438+2005, and its legal representative is Gu. The core R&D team of Katie Medical is composed of top scientists and clinical research experts in the industry, and has been deeply involved in innovative immune cell therapy technologies such as TIL/ new antigens for many years. The "super TIL" immune cell therapy technology independently developed by KATI Medical is a major upgrade of shine on you based on the world-leading TIL and CAR-T. Its products genetically modified TIL cells with the help of patented technologies such as "enhanced receptor" and "amplification factor", which completely solved the above-mentioned problems about the heterogeneity and microenvironment of solid tumors, as well as the cell amplification process, preparation cycle and cost.
In addition, the fourth generation product "Super cTIL" developed by Cartier Medical only needs to collect TIL cells in peripheral blood, which breaks through the limitation that traditional TIL treatment depends on surgical tissues. This breakthrough makes TIL therapy acceptable to almost everyone and greatly expands the applicable population.
It is reported that Beijing Katie Medical Company is the only company with innovative TIL therapy clinical research data in China. The company's previous proof-of-concept (POC) clinical research data of "Super TIL" in the treatment of advanced solid tumors that were ineffective in traditional treatment showed exciting results.
In addition, at present, a new round of clinical research on super TIL for solid tumors with different indications, even unlimited cancer species, led by well-known researchers such as Professor Li Jin from Shanghai Oriental Hospital, Professor Jun Guo from Beijing Cancer Hospital, Professor Zhao Haitao from Peking Union Medical College Hospital and Professor Zhang Yi from Zhengda First Affiliated Hospital, is under way.
Beijing Fengli Investment Co., Ltd. (referred to as "Fengli Capital" for short) takes "focusing on value-added services and striving for long-term win-win" as its corporate strategy, and is committed to becoming the "most professional and trustworthy" emerging boutique private equity investment institution, helping the invested enterprises to grow continuously and healthily and creating excellent returns for investors.
The core members of Fengyun Capital come from well-known financial investment institutions and technology enterprises such as Deutsche Bank, CITIC Securities, Bank of Communications, Jinshi Investment, Jiuding Investment, IBM and ChinaSoft. The team has an average investment experience of over 65,438+00 years, accumulated assets of nearly 100 billion, rich investment experience, extensive channel resources and excellent historical performance.
Jianxin Medical Growth Fund is a market-oriented venture capital fund under CCB International, focusing on the investment of growing medical enterprises. The fund is led by CCB International and initiated by high-quality institutions such as Kunming High-tech Group. The initial scale is 500 million yuan.
The fund makes full use of CCB International's extensive project sources in the medical and health industry, the comprehensive advantages of investment banking linkage and professional investment team, and combines the high-quality medical and health industry resources of fund investors to accurately screen scientific and technological industrialization projects in the medical and health industry and accelerate the cultivation of innovative technology enterprises. With rich investment management experience and profound industry resources, the fund provides comprehensive post-investment value-added services for the projects it invests in, and is committed to growing together with enterprises and investors.
CCB Medical Fund is a series of equity investment funds for CCB International to lay out the medical and health industry in China. The funds managed include Jianxin Medical Fund Phase I, Jianxin Medical Growth Fund and Jianxing Medical Fund.